KarXT, invented at PureTech, submitted for FDA nod in schizophrenia

Karuna Therapeutics (Nasdaq: KRTX) has taken a significant step with its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium), its ground-breaking product aiming to revolutionize the treatment of schizophrenia.

The PureTech Health (LSE: PRTC) founding clinical-stage biotech saw its shares rise 8.4% to $176.08 in ore-market activity, while PureTech’s stock fell 4.5% to 186.020 pence.

“We are thrilled to note this additional exciting milestone from the KarXT program, following the achievement of three successful, registration enabling studies in schizophrenia. KarXT, which was invented at PureTech, showcases how we invent and advance novel medicines by giving new life to drugs that have validated pharmacology but had previously not reached patients due to an issue that is now addressable with our innovations. This NDA submission is also an important milestone for patients, as it could represent the first major advance for treating schizophrenia in over 50 years if approved by the FDA,” said Eric Elenko, chief innovation officer at PureTech.